IRIS
FACCHINETTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.604
AS - Asia 1.228
EU - Europa 680
SA - Sud America 188
Continente sconosciuto - Info sul continente non disponibili 63
AF - Africa 50
Totale 3.813
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.557
SG - Singapore 508
CN - Cina 238
VN - Vietnam 192
SE - Svezia 161
IT - Italia 153
BR - Brasile 137
IE - Irlanda 132
HK - Hong Kong 98
BD - Bangladesh 69
DE - Germania 50
FR - Francia 42
ZA - Sudafrica 35
NL - Olanda 31
CA - Canada 28
IN - India 26
GB - Regno Unito 25
AT - Austria 23
TR - Turchia 20
ID - Indonesia 18
RU - Federazione Russa 15
AR - Argentina 13
JP - Giappone 13
MX - Messico 12
EC - Ecuador 11
PL - Polonia 10
CL - Cile 7
PK - Pakistan 6
PY - Paraguay 6
BE - Belgio 5
FI - Finlandia 5
BO - Bolivia 4
CO - Colombia 4
ES - Italia 4
IL - Israele 4
IQ - Iraq 4
PH - Filippine 4
UA - Ucraina 4
AL - Albania 3
KE - Kenya 3
MA - Marocco 3
RO - Romania 3
SA - Arabia Saudita 3
TH - Thailandia 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
CI - Costa d'Avorio 2
GR - Grecia 2
JO - Giordania 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
SC - Seychelles 2
TN - Tunisia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BZ - Belize 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
ZM - Zambia 1
Totale 3.753
Salva come PNG Salva come JPEG
Città #
Singapore 290
Ashburn 219
Chandler 195
San Jose 137
Santa Clara 136
Dublin 129
Dallas 108
Council Bluffs 101
Hong Kong 93
New York 65
Ho Chi Minh City 61
Beijing 58
Shanghai 50
Boardman 38
Ann Arbor 35
Hanoi 34
Lauterbourg 32
Johannesburg 30
Los Angeles 30
Princeton 23
Bremen 20
Vienna 19
Da Nang 17
Milan 15
Buffalo 14
Columbus 14
Dearborn 14
Parma 14
Des Moines 13
Jakarta 13
Rome 12
Atlanta 11
Wilmington 11
Munich 10
São Paulo 10
Tokyo 10
Chicago 9
Curitiba 9
The Dalles 9
Warsaw 9
Mexico City 8
Nanjing 8
Brooklyn 7
Frankfurt am Main 7
Haiphong 7
Izmir 7
London 7
Montreal 7
Moscow 7
Pune 7
Toronto 7
Biên Hòa 6
Bologna 6
Changsha 6
Houston 6
Phoenix 6
Quito 6
Rio de Janeiro 6
Amsterdam 5
Brussels 5
Helsinki 5
Nuremberg 5
Washington 5
Ankara 4
Belo Horizonte 4
Boston 4
Busseto 4
Can Tho 4
Cape Town 4
Denver 4
Dhaka 4
Guangzhou 4
Kunming 4
Nanchang 4
Naples 4
Orem 4
Pavia 4
Trieste 4
Baghdad 3
Buenos Aires 3
Florence 3
Francisco Morato 3
Fremont 3
Genoa 3
Grafing 3
Guayaquil 3
Hebei 3
Hải Dương 3
Istanbul 3
Jinan 3
Marseille 3
Nanning 3
Porto Alegre 3
Redondo Beach 3
Redwood City 3
Santiago 3
Seattle 3
Shenyang 3
Sumaré 3
Thái Bình 3
Totale 2.389
Salva come PNG Salva come JPEG
Nome #
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 203
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 181
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 165
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 165
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 157
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 156
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 156
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 145
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 141
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 140
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 132
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 131
Cystic brain metastases and RET fusion in lung cancer 130
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 125
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 125
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 123
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 123
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 121
Exploring the role of respiratory microbiome in lung cancer: A systematic review 118
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 114
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 112
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 101
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 101
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 99
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial 74
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 69
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis 66
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 62
ALK fusions turn sixteen in lung cancer: a review on their biology, detection and therapy 59
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 59
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 52
Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era 38
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P 37
Non-small-cell lung cancer: how to manage BRAF-mutated disease 33
Totale 3.813
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.704
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.704
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022146 0 0 0 29 2 3 27 7 9 6 7 56
2022/2023619 81 76 38 56 45 77 23 31 164 6 21 1
2023/2024229 11 19 3 2 17 80 18 17 12 10 10 30
2024/2025645 6 30 35 47 99 94 25 12 88 57 49 103
2025/20261.790 132 91 215 166 298 120 172 65 226 129 103 73
2026/2027160 67 93 0 0 0 0 0 0 0 0 0 0
Totale 3.813